What Is Daptomycin Used For? Approved Uses, Per the Label

Daptomycin is a prescription medicine, approved by the US Food and Drug Administration and supplied as a sterile powder for injection under brand names such as Cubicin and Cubicin RF as well as generic daptomycin for injection products. It is a cyclic lipopeptide antibiotic produced by Streptomyces roseosporus, and reviews of its biosynthesis described the nonribosomal peptide synthetase machinery that assembles the molecule (PMID 20522545), with related work describing genetic engineering of the lipopeptide pathway in that organism (PMID 19374996). This page is for educational purposes only and is not medical advice; consult a licensed physician or another qualified prescribing clinician about any individual health question.

The approved uses, as the US label words them

A medicine's "uses" in a regulatory sense are the indications printed in its current prescribing information. For daptomycin, the US label lists indications in two therapeutic areas, each with an adult population and a pediatric population. The exact organism lists and age ranges appear in the Indications and Usage section of the specific product's labeling, and the revision date is printed on the first page of that document.

Complicated skin and skin structure infections

The cSSSI indication is written as treatment of complicated skin and skin structure infections caused by susceptible isolates of specified Gram-positive microorganisms. The organism list in the labeling includes staphylococci and streptococci commonly implicated in these infections, together with vancomycin-susceptible Enterococcus faecalis. A 2004 review of daptomycin as a then-new antibiotic against Gram-positive pathogens summarised the spectrum of activity and the clinical development programme that supported this first indication (PMID 15500379).

Staphylococcus aureus bloodstream infections

The second indication area covers S. aureus bloodstream infections, with the adult wording including right-sided infective endocarditis caused by methicillin-susceptible and methicillin-resistant isolates. Daptomycin has since served as the comparator arm in later bacteremia research: researchers in a 2023 randomized trial published in the New England Journal of Medicine compared ceftobiprole with daptomycin in complicated Staphylococcus aureus bacteremia and reported noninferiority for ceftobiprole on the trial's primary endpoint (PMID 37754204). That trial does not change the daptomycin label, but it illustrates the role daptomycin occupies as an established treatment arm in this infection type.

The pneumonia limitation of use

The prescribing information states that daptomycin is not indicated for the treatment of pneumonia, because efficacy was not demonstrated in that setting. The pharmacological explanation discussed in the literature is inactivation of the lipopeptide by pulmonary surfactant, and the 2004 review of daptomycin pharmacology addressed the compound's behaviour at the site of infection (PMID 15500379). This limitation sits inside the Indications and Usage section itself rather than in a separate warning, which is why it belongs in any accurate answer to the question of what daptomycin is used for.

Susceptibility and stewardship wording

Like other modern antibacterial labels, the daptomycin prescribing information carries a statement that the product should be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria, and that culture and susceptibility information should guide therapy where available. The organism lists attached to each indication are therefore part of the indication, not decoration.

US label versions on DailyMed: Cubicin RF (daptomycin) for injection, DailyMed label version March 2025. The current label for the specific product governs.

Regulatory history of the indications

1. First US approval (2003). Daptomycin entered the US market with the complicated skin and skin structure infection indication in adults. Contemporary reviews described it as the first approved agent of the cyclic lipopeptide class for Gram-positive infections (PMID 15500379).
2. Bloodstream infection indication (2006). The label was expanded to include S. aureus bloodstream infections in adults, including right-sided infective endocarditis caused by methicillin-susceptible and methicillin-resistant isolates.
3. Reformulated product (Cubicin RF). A reformulated presentation was approved later with the same indications as the original product, differing in reconstitution characteristics rather than in labelled uses.
4. Pediatric indications (2017 onward). The complicated skin and skin structure infection indication and the S. aureus bacteremia indication were extended to pediatric patients within the age ranges stated in the labeling.
5. Generic entry. Multiple generic daptomycin for injection products were subsequently approved; each carries labeling that mirrors the reference product's indications, and each has its own revision date.

Readers checking a specific product should look at the revision line on the prescribing information in front of them, since labelling changes are issued product by product.

Enterococcal infections and what the label does and does not cover

Enterococci appear in the daptomycin label only through vancomycin-susceptible Enterococcus faecalis within the cSSSI organism list. Broader enterococcal use, including vancomycin-resistant Enterococcus faecium bloodstream infection, has been discussed in the literature as an area without a corresponding labelled indication: a 2010 review in the Journal of Antimicrobial Chemotherapy examined the published evidence for a potential role for daptomycin in enterococcal infections and characterised much of it as observational rather than drawn from randomized registration trials (PMID 20363805). That distinction matters for anyone reading the label literally.

Resistance and microbiology: What Studies Report

Because the indications are tied to susceptible isolates, resistance research is directly relevant to how the label reads in practice. A 2019 review in the International Journal of Medical Microbiology described MprF-mediated daptomycin resistance, explaining how alterations in this membrane lipid-modifying enzyme change the bacterial surface charge and reduce daptomycin binding (PMID 31182276). In a 2020 PLoS Biology study, researchers reported that daptomycin treatment affected resistance in off-target populations of vancomycin-resistant Enterococcus faecium, extending attention beyond the organism being treated (PMID 33332354). Laboratory work published in 2022 examined proteomic correlates of enhanced daptomycin activity after beta-lactam preconditioning in daptomycin-resistant, methicillin-resistant S. aureus, and the study reported protein expression changes accompanying restored susceptibility in vitro (PMID 35041502). None of that work alters the labelled indications; it describes the microbiological background against which susceptibility testing is interpreted.

Safety and tolerability: What Studies Report

The US prescribing information carries Warnings and Precautions covering anaphylaxis and hypersensitivity reactions, myopathy and creatine phosphokinase elevations, eosinophilic pneumonia, peripheral neuropathy, Clostridioides difficile associated diarrhea, potential effects on prothrombin time testing, and the reduced efficacy observed in pneumonia. The 2004 Expert Opinion on Pharmacotherapy review of daptomycin discussed the tolerability profile observed during its clinical development alongside its pharmacokinetics and spectrum (PMID 15500379). Monitoring requirements and individual risk assessment are matters for the prescribing clinician, and this page gives no dosing or administration directions.

Research areas that are not approved uses

A short factual note for completeness: several published lines of daptomycin research sit outside the approved indications and are not approved uses. A 2021 study in Antimicrobial Agents and Chemotherapy tested nanoencapsulated daptomycin in an experimental MRSA bone and joint infection model (PMID 34606337); a 2022 narrative review in Antibiotics surveyed reports on daptomycin and cutaneous wound healing (PMID 35884198); and a 2019 screening study identified FDA-approved drugs, daptomycin among the agents assessed, with activity against stationary phase Bartonella henselae in laboratory culture (PMID 31035691). Separately, combinatorial biosynthesis work generated novel antibiotics structurally related to daptomycin, which are experimental molecules rather than marketed products (PMID 17090667). None of these represent labelled indications.

How to read an indication statement

• Infection type plus organism plus population. Each daptomycin indication names an infection, the organisms it covers, and the patient population, and all three parts travel together.
• Limitations of use are part of the indication. The pneumonia statement sits in the same section as the approved uses.
• Product-specific labeling. Cubicin, Cubicin RF and generic daptomycin for injection products each have their own prescribing information and revision date.
• Evidence outside the label is still evidence, but it is not an indication. The 2010 enterococcal review illustrated how published experience can accumulate without a corresponding label change (PMID 20363805).

Questions better directed to a prescribing clinician

Whether daptomycin suits a particular infection, how susceptibility results should be interpreted, what monitoring applies, how renal function or concurrent medicines affect treatment decisions, and how long therapy should continue are all clinical judgements. They depend on culture data, patient history and current guidelines, and they belong to the clinician who holds the prescription. This page summarises published literature and label structure only.

For a broader overview of daptomycin's chemistry, mechanism and research history, see the hub page at /learn/daptomycin/.

References

• Daptomycin - a novel antibiotic against Gram-positive pathogens (Expert Opinion on Pharmacotherapy, 2004)
• A potential role for daptomycin in enterococcal infections: what is the evidence? (Journal of Antimicrobial Chemotherapy, 2010)
• Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia (New England Journal of Medicine, 2023)
• MprF-mediated daptomycin resistance (International Journal of Medical Microbiology, 2019)
• Daptomycin treatment impacts resistance in off-target populations of vancomycin-resistant Enterococcus faecium (PLoS Biology, 2020)
• Proteomic Correlates of Enhanced Daptomycin Activity following beta-Lactam Preconditioning in Daptomycin-Resistant, Methicillin-Resistant Staphylococcus aureus (Antimicrobial Agents and Chemotherapy, 2022)
• Efficacy of Nanoencapsulated Daptomycin in an Experimental Methicillin-Resistant Staphylococcus aureus Bone and Joint Infection Model (Antimicrobial Agents and Chemotherapy, 2021)
• Role of Daptomycin in Cutaneous Wound Healing: A Narrative Review (Antibiotics, 2022)
• Identification of FDA-Approved Drugs with Activity against Stationary Phase Bartonella henselae (Antibiotics, 2019)
• Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery (Journal of Biological Chemistry, 2010)
• Biosynthesis and genetic engineering of lipopeptides in Streptomyces roseosporus (Methods in Enzymology, 2009)
• Combinatorial biosynthesis of novel antibiotics related to daptomycin (PNAS, 2006)